Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG‑2 hepatocellular carcinoma cells

Liu,Ying; Ban,Li‑Ying; Su,Xi; Gao,Shan; Liu,Ji‑Wei; Cui,Xiao‑Nan

doi:10.3892/mmr.2015.3552

Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG‑2 hepatocellular carcinoma cells

Authors:
- Ying Liu
- Li‑Ying Ban
- Xi Su
- Shan Gao
- Ji‑Wei Liu
- Xiao‑Nan Cui
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
Published online on: March 26, 2015 https://doi.org/10.3892/mmr.2015.3552
Pages: 1598-1604

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of cinobufacini injection on the proliferation and expression of topoisomerases in human HepG‑2 hepatocarcinoma cells. The cells were divided into a control group and an experimental group, in which 0.105, 0.21, 0.42 mg/l cinobufacini was injected. Cell proliferation was assessed using a 3‑(4,5‑dimethylthiazol‑2‑yl) ‑2,5‑diphenyltetrazolium bromide assay, levels of apoptosis were detected using annexin V/propidium iodide staining and cell cycles were analyzed using flow cytometric analysis. The mRNA and protein expression levels of topoisomerase (TOPO) I and TOPO Ⅱ were determined by reverse transcription‑quantitative polymerase chain reaction and western blotting, respectively. Cinobufacini injection significantly inhibited the proliferation of the HepG‑2 cells (P<0.05), induced apoptosis (P<0.05) in a dose‑ and time‑dependent manner, induced tumor cell arrest at the S phase in a dose‑dependent manner, and downregulated the mRNA and protein expression levels of TOPO I and TOPO Ⅱ (P<0.05) in a dose‑dependent manner. Therefore, cinobufacini was found to inhibit human HepG‑2 hepatocellular carcinoma cell proliferation, and downregulation of the expression levels of TOPO I and TOPO Ⅱ may contribute to the effect on proliferation observed in the Hep‑G2 cells following cinobbufacini injection.

View Figures

View References

1	Xie RF, Li ZC, Gao B, Shi ZN and Zhou X: Bufothionine, a possible effective component in cinobufocini injection for hepatocellular carcinoma. J Ethnopharmacol. 141:692–700. 2012. View Article : Google Scholar : PubMed/NCBI
2	Qi F, Li A, Inagaki Y, Kokudo N, Tamura S, Nakata M and Tang W: Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol. 11:342–349. 2011. View Article : Google Scholar
3	Gong ZP and Chen T: Studies on analgesic mechanism based on opioid receptor for cinobufagin injection. Chin J Exp Tradit Med. 16:1202010.In Chinese.
4	Liu HM, Zheng YL and Liu XL: A Clinical study of efficacy of cinobufagin injection combined with ND formula in medium and advanced esophageal patients. Chin J Exp Tradit Med. 17:2352011.In Chinese.
5	Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, Li XK and Tang W: Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 4:297–307. 2010.
6	Su YH, Yin XC, Xie JM, et al: Inhibition effects of three kinds of bufotoxins on human SMMC-7721 and BEL-7402 hepatoma cells lines. Acad J Second Mil Med Univ. 24:3932004.
7	Yang LH, Jing XQ and Zhang W: Studies on the chemical constituents from the skin of Bufo bufo gargarizans cantor. J Shenyang Pharm Univ. 17:292–295. 2000.
8	Sun Y and Shi KY: Primary carcinoma of the liver. Manual of Medical Oncology. Fifth Edition. Sun Y: People’s medical publishing house; Bei Jing: pp. 5392007
9	Zhou LX and Guo JM: Research progress in targeted therapy for hepatocellular carcinoma. J Oncol. 15:1562009.
10	Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind placebo controlled tril. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
11	Cui X, et al: New reseach approaches in DNA topoisomerase II targets and antitumor drug. Qingdao Med J. 36:434–437. 2004.In Chinese.
12	Sun Y, Shan LJ, Liu YJ and Cui XN: The effect of cinobufacini injection on DNA topoisomerase I of human hepatocellular carcinoma HepG-2 cells. Chin J Oncol. 19:410–413. 2010.In Chinese.
13	Belluti S, Basile V, Benatti P, Ferrari E, Marverti G and Imbriano C: Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells. Cell Death Dis. 4:e7562013. View Article : Google Scholar
14	Bradford MM: A rapid and sensitive for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
15	Stoscheck CM: Quantitation of protein. Methods Enzymol. 182:50–68. 1990.PubMed/NCBI
16	Zhong JS, Chen GP and Guo JW: Clinical observation on HuaChanSu in treating hepatocellular carcinoma after trans-arterial chemoembolization (TACE). Cancer Prev Treat. 29:67–69. 2002.
17	Meng ZQ, Yang PY, Shen YH, et al: Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 115:5309–5318. 2009. View Article : Google Scholar : PubMed/NCBI
18	Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP and Pan BR: Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol. 14:5210–5216. 2008. View Article : Google Scholar : PubMed/NCBI
19	Yeh JY and Huang WJ: Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate. 54:112–124. 2003. View Article : Google Scholar
20	Yu CH, Kan SF, Pu HF, Jea Chien E and Wang PS: Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci. 99:2467–2476. 2008. View Article : Google Scholar : PubMed/NCBI
21	Qi F, Inagaki Y, Gao B, et al: Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci. 102:951–958. 2011. View Article : Google Scholar : PubMed/NCBI
22	Qi F, Li A, Inagaki Y, et al: Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol. 11:342–349. 2011. View Article : Google Scholar
23	Denny WA and Baguley BC: Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem. 3:339–353. 2003. View Article : Google Scholar : PubMed/NCBI
24	Fayad W, Fryknäs M, Brnjic S, Olofsson MH, Larsson R and Linder S: Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. PLoS One. 4:e72382009. View Article : Google Scholar : PubMed/NCBI
25	Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer inxenografts. Science. 246:1046–1048. 1989. View Article : Google Scholar : PubMed/NCBI
26	Potmesil M, Hsiang YH, Liu LF, et al: Resistance of humanleukemic and normal lymphocytes to drug-induced DNAcleavage and low levels of DNA topoisomerase II. Cancer Res. 48:3537–3543. 1988.PubMed/NCBI
27	Rho YH, Lee BW, Park KH, et al: Cudraflavanone A purified from Cudrania tricuspidata induces apoptotic cell death of human leukemia U937 cells, at least in part, through the inhibition of DNA topoisomerase I and protein kinase C activity. Anti-cancer Drugs. 18:1023–1028. 2007. View Article : Google Scholar : PubMed/NCBI
28	Pan YQ, Yuan G and Yang YW: DNA topoisomerase IIα and tumor. Med Imformation. 2:4152011.
29	Squires S, Ryan AJ, Strutt HL, Smith PJ and Johnson RT: Deoxyguanosine enhances the cytotoxicity of the topoisomerase I inhibitor camptothecin by reducing the repair of double-strand breaks induced in replicating DNA. J Cell Sci. 100:883–893. 1991.PubMed/NCBI
30	Huang X, Halicka HD, Traganos F, et al: Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis. Cell Prolif. 38:223–243. 2005. View Article : Google Scholar : PubMed/NCBI
31	Liu YP, Chen HL, Tzeng CC, et al: TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells. Breast Cancer Res Treat. 138:383–393. 2013. View Article : Google Scholar : PubMed/NCBI
32	Hofland K, Petersen BO, Falck J, Helin K, Jensen PB and Sehested M: Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex. Clin Cancer Res. 6:1488–1497. 2000.PubMed/NCBI
33	Nitiss John L and Wang James C: Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Harmacology. 50:1095–1102. 1996.